This content is from: Patents

Gilead ordered to pay $200m for infringing Merck hepatitis C patents

Jury awards figure that is 10% of the $2 billion Merck was seeking for Gilead infringing hepatitis C treatment patents

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.

Related